Drug Trial Radar · NCT06655896
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Oct 29, 2024
Primary completion
Nov 30, 2028
Study completion Aug 30, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Conditions
- Scleroderma, Diffuse
Interventions
rapcabtagene autoleucelBiological
single infusion of rapcabtagene autoleucel after lymphodepleting therapy with fludarabine (adjusted based on renal impairment) and cyclophosphamide daily for 3 days.
rituximabBiological
rituximab intravenous infusion (i.v.) as per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement of a treatment response as per the Revised Composite Response Index in Systemic Sclerosis 50 (rCRISS50) definition at Week 52.Time frame: Week 52
Locations
93 sites in 22 countries. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
UCSF
San Francisco, California
Sutter Health Network
San Pablo, California
FL Medical Clinic Orlando Health
Zephyrhills, Florida
Northwestern University
Chicago, Illinois
University Of Iowa
Iowa City, Iowa
Boston Medical Center
Boston, Massachusetts
Michigan Med University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
James Cancer Hospital
Columbus, Ohio
Oregon Health Sciences University
Portland, Oregon
Avera Cancer
Sioux Falls, South Dakota
LDS Hospital
Salt Lake City, Utah
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Novartis Investigative Site
Camperdown, New South Wales, Australia
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Olomouc, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Aarhus N, Denmark
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Lübeck, Germany
Novartis Investigative Site
Mainz, Germany
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.